1. Background
2. Objectives
3. Patients and Methods
3.1. Isolates and Preparation of Standard Suspension
3.2. Phospholipase Activity
3.3. Proteinase Activity
3.4. Coagulase Activity
3.5. Susceptibility to Fluconazole
4. Results
| Candida Spp | Healthy Individuals | Patients With Candida Vaginitis |
|---|---|---|
| C. albicans | 19 (45.2) | 32 (48.5) |
| C. glabrata | 11 (26.2) | 15 (22.7) |
| C.dubliniensis | 2 (4.8) | 11 (16.7) |
| C. tropicalis | 1 (2.4) | 1 (1.5) |
| C. parapsilosis | 4 (9.5) | 0 (0.0) |
| C. guilliermondii | 0 (0.0) | 1 (1.5) |
| C. kefyr | 1 (2.4) | 3 (4.5) |
| C. humicola | 0 (0.0) | 1 (1.5) |
| Candida spp. | 4 (9.5) | 2 (3.1) |
aData are presented as No. (%).
4.1. Phospholipase Activity
| Candida Spp | Healthy Individuals | Patients With Vaginitis | ||
|---|---|---|---|---|
| Negative | Positive | Negative | Positive | |
| C. albicans | 2 (4.8) | 17 (40.5) | 5 (6.1) | 28 (42.4) |
| C. dubliniensis | 0 (0.0) | 2 (4.8) | 1 (1.5) | 10 (15.2) |
| C. glabrata | 9 (21.4) | 2 (4.8) | 12 (18.2) | 3 (4.5) |
| C. tropicalis | 1 (2.4) | 0 (0.0) | 0 (0.0) | 1 (1.5) |
| C. parapsilosis | 9 (21.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| C. guilliermondii | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.5) |
| C. kefyr | 1 (2.4) | 0 (0.0) | 3 (4.5) | 0 (0.0) |
| C. humicola | 0 (0.0) | 0 (0.0) | 1 (1.5) | 0 (0.0) |
| Candida spp | 2 (4.8) | 2 (4.8) | 1 (1.5) | 1 (1.5) |
aData are presented as No. (%).
4.2. Proteinase Activity
| Candida Spp | Healthy Individuals | Patients With Vaginitis | ||
|---|---|---|---|---|
| Negative | Positive | Negative | Positive | |
| C. albicans | 7 (16.7) | 12 (28.6) | 8 (12.1) | 24 (36.4) |
| C. dubliniensis | 1 (2.4) | 1 (2.4) | 4 (6.1) | 7 (10.6) |
| C. glabrata | 7 (16.7) | 4 (9.5) | 3 (4.5) | 12 (8.2) |
| C. tropicalis | 0 (0.0) | 1 (2.4) | 1 (1.5) | 0 (0.0) |
| C. parapsilosis | 0 (0.0) | 4 (9.5) | 0 (0.0) | 0 (0.0) |
| C. guilliermondii | 0 (0.0) | 0 (0.0) | 1 (1.5) | 0 (0.0) |
| C. kefyr | 0 (0.0) | 1 (2.4) | 0 (0.0) | 3 (4.5) |
| C. humicola | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.5) |
| Candida spp | 1 (2.4) | 3 (7.1) | 0 (0.0) | 2 (3) |
aData are presented as No. (%).
4.3. Coagulase Activity
4.4. Susceptibility to Fluconazole
| Candida Spp | Resistant | Dose Dependent | Sensitive |
|---|---|---|---|
| C. albicans | 13 (19.7) | 4 (6.1) | 15 (22.7) |
| C. dubliniensis | 6 (9.1) | 1 (1.5) | 4 (6.1) |
| C. glabrata | 3 (4.5) | 2 (3.1) | 10 (15.2) |
| C. tropicalis | 0 (0.0) | 1 (1.5) | 0 (0.0) |
| C. guilliermondii | 0 (0.0) | 0 (0.0) | 1 (1.5) |
| C. kefyr | 0 (0.0) | 0 (0.0) | 3 (4.5) |
| C. humicola | 0 (0.0) | 0 (0.0) | 1 (1.5) |
| Candida spp | 1 (1.5) | 0 (0.0) | 1 (1.5) |
aData are presented as No. (%).

